Recently, the Category 1 innovative drug Ritlecitinib Tosylate Capsules (trade name: LITFULO ®) of Pfizer Inc. is approved for marketing through priority review and approval procedures by China NMPA. This drug is indicated for treating severe alopecia areata for adults and adolescents 12 years old and older.

Ritlecitinib is a kinase inhibitor, which can irreversibly inhibit Janus kinase 3 (JAK3) and the tyrosine kinase(TEC) family. The marketing of this drug provides new treatment options for patients with severe alopecia areata.